AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ibudilast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiasthmatics or antiallergics, not acting primarily as antihistaminics anti-allergic or anti-inflammatory, not acting as anti-histaminics | 1406 | 50847-11-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 1, 1989 | PMDA | Kyorin Pharmaceutical |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Body tinea | 294.26 | 236.92 | 45 | 988 | 2103 | 90625311 |
| Inhibitory drug interaction | 269.69 | 236.92 | 44 | 989 | 3119 | 90624295 |
| Infection susceptibility increased | 267.14 | 236.92 | 45 | 988 | 3881 | 90623533 |
| Poor quality sleep | 258.36 | 236.92 | 59 | 974 | 24634 | 90602780 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Body tinea | 293.77 | 137.66 | 44 | 1045 | 2071 | 110586139 |
| Infection susceptibility increased | 261.58 | 137.66 | 44 | 1045 | 4354 | 110583856 |
| Inhibitory drug interaction | 249.58 | 137.66 | 43 | 1046 | 4904 | 110583306 |
| Poor quality sleep | 248.51 | 137.66 | 57 | 1032 | 28020 | 110560190 |
| Glucose tolerance impaired | 226.21 | 137.66 | 44 | 1045 | 9793 | 110578417 |
| Bone density decreased | 204.75 | 137.66 | 44 | 1045 | 15998 | 110572212 |
| Impaired quality of life | 202.82 | 137.66 | 49 | 1040 | 29968 | 110558242 |
| Impaired work ability | 198.52 | 137.66 | 47 | 1042 | 26372 | 110561838 |
| Purpura | 196.95 | 137.66 | 46 | 1043 | 24342 | 110563868 |
| Hyperlipidaemia | 169.56 | 137.66 | 44 | 1045 | 35804 | 110552406 |
| Oral herpes | 169.28 | 137.66 | 44 | 1045 | 36036 | 110552174 |
| Skin disorder | 161.71 | 137.66 | 44 | 1045 | 42869 | 110545341 |
| Cataract | 139.02 | 137.66 | 45 | 1044 | 79440 | 110508770 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R03DC04 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Leukotriene receptor antagonists |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D010726 | Phosphodiesterase Inhibitors |
| MeSH PA | D010975 | Platelet Aggregation Inhibitors |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
Related Drugs by ATC class:
R03DC Leukotriene receptor antagonists 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Asthma | indication | 195967001 | DOID:2841 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | IC50 | 5.80 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Enzyme | IC50 | 7.19 | CHEMBL | |||||
| cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 5.46 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 7.27 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Enzyme | IC50 | 6.78 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Enzyme | IC50 | 6.62 | CHEMBL | |||||
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Enzyme | IC50 | 5.57 | CHEMBL | |||||
| Macrophage migration inhibitory factor | Cytokine | Kd | 5.85 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01385 | KEGG_DRUG |
| C0123047 | UMLSCUI |
| CHEBI:31684 | CHEBI |
| CHEMBL19449 | ChEMBL_ID |
| DB05266 | DRUGBANK_ID |
| CHEMBL395091 | ChEMBL_ID |
| 3671 | PUBCHEM_CID |
| C038366 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7399 | IUPHAR_LIGAND_ID |
| 6068 | INN_ID |
| M0TTH61XC5 | UNII |
| 010937 | NDDF |
| AVL | PDB_CHEM_ID |
| M0TTH61XC5 | INXIGHT DRUGS |
Pharmaceutical products:
None